Journal of Applied PharmacyPharmaceutics
FDA Approves Asundexian (Sunharbo), the First Factor XIa Inhibitor for Secondary Stroke Prevention
The US FDA has approved Bayer's asundexian (Sunharbo), the first factor XIa inhibitor, to reduce recurrent stroke risk after a non-cardioembolic ischaemic stroke or high-risk TIA. The decision validates a new anticoagulant class designed to separate antithrombotic benefit from bleeding risk.
Editorial Office | Journal of Applied Pharmacy. Announcements and updates prepared by the journal's editorial office.
The US Food and Drug Administration (FDA) approved asundexian (Sunharbo, Bayer) on 9 November 2026 as a novel drug to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack¹. The 50 mg once-daily tablet is the first factor XIa (FXIa) inhibitor to reach the US market¹, following Priority Review granted in May 2026 and a Fast Track designation in 2023³. The decision extends a first-in-world approval by China's National Medical Products Administration in October 2026².
Factor XI sits within the intrinsic arm of the coagulation cascade and contributes substantially to pathological thrombus propagation, while playing a comparatively limited role in physiological haemostasis. Selective FXIa inhibition is therefore hypothesised to prevent thrombotic events with less bleeding than agents acting on factor Xa or thrombin. The approval rests on the global, randomised, double-blind, placebo-controlled Phase III OCEANIC-STROKE trial of 12,327 participants, in which asundexian was added to single or dual antiplatelet therapy². The study met its primary efficacy outcome (time to first ischaemic stroke) and its primary safety outcome (time to ISTH major bleeding)³, with a company-reported 26% relative reduction in ischaemic stroke that was consistent across age, sex and stroke subtype². The results were presented at the International Stroke Conference 2026 and published in The New England Journal of Medicine³.
The approval gives Bayer first-mover advantage in the FXIa class in both China² and the United States¹. Clinically, prescribers gain an adjunctive option for a population in which roughly one in ten survivors has another stroke within a year despite current prevention². Scientifically, a successful launch would provide real-world support for the thrombosis–haemostasis separation hypothesis underpinning the entire FXI/FXIa drug class. Long-term safety in broad clinical use, bleeding outcomes alongside dual antiplatelet therapy outside trial settings, and payer positioning remain to be established.
References
1U.S. Food and Drug Administration. (2026). Novel Drug Approvals for 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
Credence Research. (2026, October). China approves Bayer's asundexian, the first factor XIa inhibitor, for secondary stroke prevention. https://www.credenceresearch.com/news/china-approves-bayer-asundexian-sunharbo-first-factor-xia-inhibitor-stroke-prevention
Bayer / Business Wire. (2026, May 18). Bayer granted Priority Review by U.S. FDA for asundexian. https://www.businesswire.com/news/home/20260518787299/en/Bayer-Granted-Priority-Review-by-U.S.-FDA-for-Asundexian-in-Patients-After-a-Non-Cardioembolic-Ischemic-Stroke-or-Transient-Ischemic-Attack
Reporting: Editorial Desk | Independent reporting synthesis; authoritative publications, official records, institutional archives, publicly accessible documentation, AI-assisted research, cross-referencing, factual verification and retrieval metadata.
Disclaimer: This article is provided for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or investment advice. Prescribing decisions should be based on the official product labelling and the judgement of a qualified healthcare professional. Financial figures and forward-looking statements are reported as disclosed by the companies concerned and are subject to change. Readers should consult the cited primary sources before relying on any information presented here.